Cargando…

The Role of Myeloid Cells in GBM Immunosuppression

Gliomas are intrinsic brain tumors that originate from glial cells. Glioblastoma (GBM) is the most aggressive glioma type and resistant to immunotherapy, mainly due to its unique immune environment. Dimensional data analysis reveals that the intra-tumoral heterogeneity of immune cell populations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ya-Jui, Wu, Caren Yu-Ju, Wu, Janet Yuling, Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192945/
https://www.ncbi.nlm.nih.gov/pubmed/35711434
http://dx.doi.org/10.3389/fimmu.2022.887781
_version_ 1784726339538911232
author Lin, Ya-Jui
Wu, Caren Yu-Ju
Wu, Janet Yuling
Lim, Michael
author_facet Lin, Ya-Jui
Wu, Caren Yu-Ju
Wu, Janet Yuling
Lim, Michael
author_sort Lin, Ya-Jui
collection PubMed
description Gliomas are intrinsic brain tumors that originate from glial cells. Glioblastoma (GBM) is the most aggressive glioma type and resistant to immunotherapy, mainly due to its unique immune environment. Dimensional data analysis reveals that the intra-tumoral heterogeneity of immune cell populations in the glioma microenvironment is largely made up of cells of myeloid lineage. Conventional therapies of combined surgery, chemotherapy and radiotherapy have achieved limited improvements in the prognosis of glioma patients, as myeloid cells are prominent mediators of immune and therapeutic responses—like immunotherapy resistance—in glioma. Myeloid cells are frequently seen in the tumor microenvironment (TME), and they are polarized to promote tumorigenesis and immunosuppression. Reprogramming myeloid cells has emerged as revolutionary, new types of immunotherapies for glioma treatment. Here we detail the current advances in classifying epigenetic, metabolic, and phenotypic characteristics and functions of different populations of myeloid cells in glioma TME, including myeloid-derived suppressor cells (MDSCs), glioma-associated microglia/macrophages (GAMs), glioma-associated neutrophils (GANs), and glioma-associated dendritic cells (GADCs), as well as the mechanisms underlying promotion of tumorigenesis. The final goal of this review will be to provide new insights into novel therapeutic approaches for specific targeting of myeloid cells to improve the efficacy of current treatments in glioma patients.
format Online
Article
Text
id pubmed-9192945
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91929452022-06-15 The Role of Myeloid Cells in GBM Immunosuppression Lin, Ya-Jui Wu, Caren Yu-Ju Wu, Janet Yuling Lim, Michael Front Immunol Immunology Gliomas are intrinsic brain tumors that originate from glial cells. Glioblastoma (GBM) is the most aggressive glioma type and resistant to immunotherapy, mainly due to its unique immune environment. Dimensional data analysis reveals that the intra-tumoral heterogeneity of immune cell populations in the glioma microenvironment is largely made up of cells of myeloid lineage. Conventional therapies of combined surgery, chemotherapy and radiotherapy have achieved limited improvements in the prognosis of glioma patients, as myeloid cells are prominent mediators of immune and therapeutic responses—like immunotherapy resistance—in glioma. Myeloid cells are frequently seen in the tumor microenvironment (TME), and they are polarized to promote tumorigenesis and immunosuppression. Reprogramming myeloid cells has emerged as revolutionary, new types of immunotherapies for glioma treatment. Here we detail the current advances in classifying epigenetic, metabolic, and phenotypic characteristics and functions of different populations of myeloid cells in glioma TME, including myeloid-derived suppressor cells (MDSCs), glioma-associated microglia/macrophages (GAMs), glioma-associated neutrophils (GANs), and glioma-associated dendritic cells (GADCs), as well as the mechanisms underlying promotion of tumorigenesis. The final goal of this review will be to provide new insights into novel therapeutic approaches for specific targeting of myeloid cells to improve the efficacy of current treatments in glioma patients. Frontiers Media S.A. 2022-05-31 /pmc/articles/PMC9192945/ /pubmed/35711434 http://dx.doi.org/10.3389/fimmu.2022.887781 Text en Copyright © 2022 Lin, Wu, Wu and Lim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lin, Ya-Jui
Wu, Caren Yu-Ju
Wu, Janet Yuling
Lim, Michael
The Role of Myeloid Cells in GBM Immunosuppression
title The Role of Myeloid Cells in GBM Immunosuppression
title_full The Role of Myeloid Cells in GBM Immunosuppression
title_fullStr The Role of Myeloid Cells in GBM Immunosuppression
title_full_unstemmed The Role of Myeloid Cells in GBM Immunosuppression
title_short The Role of Myeloid Cells in GBM Immunosuppression
title_sort role of myeloid cells in gbm immunosuppression
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192945/
https://www.ncbi.nlm.nih.gov/pubmed/35711434
http://dx.doi.org/10.3389/fimmu.2022.887781
work_keys_str_mv AT linyajui theroleofmyeloidcellsingbmimmunosuppression
AT wucarenyuju theroleofmyeloidcellsingbmimmunosuppression
AT wujanetyuling theroleofmyeloidcellsingbmimmunosuppression
AT limmichael theroleofmyeloidcellsingbmimmunosuppression
AT linyajui roleofmyeloidcellsingbmimmunosuppression
AT wucarenyuju roleofmyeloidcellsingbmimmunosuppression
AT wujanetyuling roleofmyeloidcellsingbmimmunosuppression
AT limmichael roleofmyeloidcellsingbmimmunosuppression